Time-course of neopterin levels in patients suffering from severe sepsis treated with and without Drotrecogin-alpha (activated)

被引:4
作者
Behnes, Michael [1 ]
Brueckmann, Martina [1 ]
Wiessner, Mike [1 ]
Kettenmann, Eva [1 ]
Liebetrau, Claudia [1 ]
Lang, Siegfried [1 ]
Putensen, Christian [2 ]
Borggrefe, Martin [1 ]
Hoffmann, Ursula [1 ]
机构
[1] Univ Heidelberg, Fac Med, Dept Med 1, D-68167 Mannheim, Germany
[2] Univ Bonn, Dept Anaesthesiol, D-5300 Bonn, Germany
关键词
D O I
10.1080/00365540701808978
中图分类号
R51 [传染病];
学科分类号
100401 [流行病与卫生统计学];
摘要
Neopterin is secreted by activated monocytes/macrophages upon stimulation with interferon-gamma. The release of this pro-inflammatory mediator permits the activation status of cell-mediated immune system to be examined. We assayed neopterin plasma concentrations in septic patients under treatment with (n = 10) and without Drotrecogin-alpha (activated) (n = 10) on d 1 and 6 of severe sepsis. In septic patients treated with Drotrecogin-alpha (activated), neopterin levels decreased significantly (p = 0.027) from d 1 (baseline) (mean 140.8 nmol/l, +/- standard error of mean (SEM) 106.2) to d 6 (mean 68.9 nmol/l, +/- SEM 46.4). In patients not treated with Drotrecogin-alpha (activated) there was no significant (p = 0.96) decrease of neopterin levels from d 1 mean 147.8 nmol/l, +/- SEM 58.4) to d 6 (mean 139.7 nmol/l, +/- SEM 52.6). Furthermore, neopterin levels showed significant correlations with bilirubin in all patient groups on d 1 of severe sepsis (range of correlation coefficient, r : 0.69-0.88; p < 0.05). Neopterin levels correlated significantly with creatinine with regard to all patient groups (range of correlation coefficient, r: 0.73-0.92; p < 0.05). In conclusion, Drotrecogin-alpha (activated) was associated with a significant decrease of neopterin plasma levels in septic patients. Neopterin concentrations appear to depend on renal function and enterohepatic circulation.
引用
收藏
页码:503 / 508
页数:6
相关论文
共 24 条
[1]
Efficacy and safety of recombinant human activated protein C for severe sepsis. [J].
Bernard, GR ;
Vincent, JL ;
Laterre, P ;
LaRosa, SP ;
Dhainaut, JF ;
Lopez-Rodriguez, A ;
Steingrub, JS ;
Garber, GE ;
Helterbrand, JD ;
Ely, EW ;
Fisher, CJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (10) :699-709
[2]
Sepsis: A new hypothesis for pathogenesis of the disease process [J].
Bone, RC ;
Grodzin, CJ ;
Balk, RA .
CHEST, 1997, 112 (01) :235-243
[3]
DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[4]
URINARY NEOPTERIN IN VOLUNTEERS EXPERIMENTALLY INFECTED WITH PLASMODIUM-FALCIPARUM [J].
BROWN, AE ;
HERRINGTON, DA ;
WEBSTER, HK ;
CLYDE, DF ;
SZTEIN, MB ;
DAVIS, JR ;
BEIER, MS ;
EDELMAN, R .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1992, 86 (02) :134-136
[5]
Drotrecogin alfa (activated) inhibits NF-kappa B activation and MIP-1-alpha release from isolated mononuclear cells of patients with severe sepsis [J].
Brueckmann, M ;
Hoffmann, U ;
Dvortsak, E ;
Lang, S ;
Kaden, JJ ;
Borggrefe, M ;
Haase, KK .
INFLAMMATION RESEARCH, 2004, 53 (10) :528-533
[6]
Activated protein C inhibits the release of macrophage inflammatory protein-1-alpha from THP-1 cells and from human monocytes [J].
Brueckmann, M ;
Hoffmann, U ;
de Rossi, L ;
Weller, HM ;
Liebe, V ;
Lang, S ;
Kaden, JJ ;
Borggrefe, M ;
Haase, KK ;
Huhle, G .
CYTOKINE, 2004, 26 (03) :106-113
[7]
Drotrecogin alfa (activated) does not affect intracellular production of interleukin-6 and tumor necrosis factor-α in endotoxin-stimulated human monocytes [J].
Czeslick, EG ;
Nestler, F ;
Simm, A ;
Struppert, A ;
Sablotzki, A .
ANESTHESIA AND ANALGESIA, 2005, 101 (06) :1805-1808
[8]
Dynamic evolution of coagulopathy in the first day of severe sepsis: Relationship with mortality and organ failure [J].
Dhainaut, JF ;
Shorr, AF ;
Macias, WL ;
Kollef, MJ ;
Levi, M ;
Reinhart, K ;
Nelson, DR .
CRITICAL CARE MEDICINE, 2005, 33 (02) :341-348
[9]
Treatment effects of drotrecogin alfa (activated) in patients with severe sepsis with or without overt disseminated intravascular coagulation [J].
Dhainaut, JF ;
Yan, SB ;
Joyce, DE ;
Pettilä, V ;
Basson, B ;
Brandt, JT ;
Sundin, DP ;
Levi, M .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2004, 2 (11) :1924-1933
[10]
Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis [J].
Dhainaut, JFO ;
Yan, SB ;
Margolis, BD ;
Lorente, JA ;
Russell, JA ;
Freebairn, RC ;
Spapen, HD ;
Riess, H ;
Basson, B ;
Johnson, G ;
Kinasewitz, GT .
THROMBOSIS AND HAEMOSTASIS, 2003, 90 (04) :642-653